
- /
- Supported exchanges
- / US
- / EWTX.NASDAQ
Edgewise Therapeutics Inc (EWTX NASDAQ) stock market data APIs
Edgewise Therapeutics Inc Financial Data Overview
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Edgewise Therapeutics Inc data using free add-ons & libraries
Get Edgewise Therapeutics Inc Fundamental Data
Edgewise Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -167 928 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.4211
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Edgewise Therapeutics Inc News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”) (NASDAQ: EWTX). Such i...


INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”) (NASDAQ: EWTX). Such inv...

Edgewise Therapeutics Reports Positive Results for Muscular Dystrophy Treatment
Edgewise Therapeutics Inc. (NASDAQ:EWTX) is one of the best up and coming stocks to invest in now. On June 26, Edgewise Therapeutics announced positive results from its sevasemten program for Becker a...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”) (NASDAQ: EWTX). Such i...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.